Literature DB >> 10479659

Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice.

K Tsukamoto1, R Tangirala, S H Chun, E Puré, D J Rader.   

Abstract

Apolipoprotein E (apoE) is a multifunctional protein synthesized by the liver and tissue macrophages. ApoE-deficient mice have severe hyperlipidemia and develop accelerated atherosclerosis on a chow diet. Both liver-derived and macrophage-derived apoEs have been shown to reduce plasma lipoprotein levels and slow the progression of atherosclerosis in apoE-deficient mice, but regression of atherosclerosis has not been demonstrated in this model. We utilized second-generation adenoviruses to achieve hepatic expression of human apoE in chow-fed, apoE-deficient mice with established atherosclerotic lesions of different stages. As expected, hepatic expression of human apoE3 significantly reduced plasma cholesterol levels. Liver-derived apoE also accumulated substantially within preexisting atherosclerotic lesions, indicating that plasma apoE gained access to the arterial intima. Hepatic expression of human apoE3 for 6 weeks resulted in significant quantitative regression of both early fatty streak lesions as well as advanced, complex lesions in both the aortic root and the aortic arch. In addition, hepatic expression of apoE induced substantial morphological changes in lesions, including decreased foam cells and increased smooth muscle cells and extracellular matrix content. In parallel, human apoE4 and apoE2 were also expressed in the liver by using recombinant adenoviruses. ApoE4 reduced cholesterol levels to the same extent as did apoE3 and also prevented progression but did not induce significant regression of preexisting lesions. ApoE2 reduced cholesterol levels to a lesser degree than did apoE3 and apoE4 and lesion progression was reduced, but regression was not induced. In summary, (1) regression of preexisting atherosclerotic lesions in apoE-deficient mice can be rapidly induced by hepatic expression of apoE, despite the absence of macrophage-derived apoE; (2) the morphological changes seen in this model of regression resemble those in other animal models, induced over longer periods of time; (3) liver-derived apoE gained access to and was retained by intimal atherosclerotic lesions; and (4) apoE4 was less effective in inducing regression, despite its effects on plasma lipoproteins that were similar to those of apoE3. The rapid regression of preexisiting atherosclerotic lesions induced by apoE gene transfer in apoE-deficient mice could provide a convenient murine model for investigation of the molecular events associated with atherosclerosis regression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479659     DOI: 10.1161/01.atv.19.9.2162

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  29 in total

1.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

2.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.

Authors:  Erin D MacDougall; Farah Kramer; Patti Polinsky; Shelley Barnhart; Bardia Askari; Fredrik Johansson; Rebecca Varon; Michael E Rosenfeld; Kazuhiro Oka; Lawrence Chan; Stephen M Schwartz; Karin E Bornfeldt
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Using Mendelian Randomization studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine.

Authors:  Wei Zhao; Jung-Jin Lee; Asif Rasheed; Danish Saleheen
Journal:  Curr Genet Med Rep       Date:  2016-09-10

Review 4.  Animal models of atherosclerosis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

5.  ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

6.  HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells.

Authors:  Jonathan E Feig; James X Rong; Raanan Shamir; Marie Sanson; Yuliya Vengrenyuk; Jianhua Liu; Katey Rayner; Kathryn Moore; Michael Garabedian; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

7.  Effect of the Kv1.3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model.

Authors:  Xiaofen Wu; Rende Xu; Ming Cao; Lei Ruan; Xingfen Wang; Cuntai Zhang
Journal:  Heart Vessels       Date:  2014-01-19       Impact factor: 2.037

8.  Novel Reversible Model of Atherosclerosis and Regression Using Oligonucleotide Regulation of the LDL Receptor.

Authors:  Debapriya Basu; Yunying Hu; Lesley-Ann Huggins; Adam E Mullick; Mark J Graham; Tomasz Wietecha; Shelley Barnhart; Allison Mogul; Katharina Pfeiffer; Andreas Zirlik; Edward A Fisher; Karin E Bornfeldt; Florian Willecke; Ira J Goldberg
Journal:  Circ Res       Date:  2018-01-10       Impact factor: 17.367

9.  Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice.

Authors:  Min Liu; David G Kuhel; Ling Shen; David Y Hui; Stephen C Woods
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-29       Impact factor: 3.619

10.  Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice.

Authors:  Catherine Martel; Wenjun Li; Brian Fulp; Andrew M Platt; Emmanuel L Gautier; Marit Westerterp; Robert Bittman; Alan R Tall; Shu-Hsia Chen; Michael J Thomas; Daniel Kreisel; Melody A Swartz; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.